Section Arrow
TVTX.NASDAQ
- Travere Therapeutics
Quotes are at least 15-min delayed:2026/11/04 08:49 EST
Pre Market
Last
 50.89
+1.48 (+3.00%)
Bid
42.9
Ask
51
High 51.0322 
Low 44.5 
Volume 1.81K 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
49.41 
1-M High
-- 
Volume 
-- 
Bid
42.9
Ask
51
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
4.66B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.46/1.36
Enterprise Value
4.98B
Balance Sheet
Book Value Per Share
0.26
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
490.73M
Operating Revenue Per Share
2.46
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 30.99 +0.86 +2.85%
ZVRAZevra Therapeutics-------- 
Pre Market 10.26 0 0.00%
ZURAZura Bio Limited-------- 
Pre Market 4.054 +0.064 +1.60%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 1.78 0 0.00%
ZLABZai Lab Limited-------- 
Pre Market 23.0747 +1.1147 +5.08%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.